Xyotec Capsule 200 contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various systemic and superficial fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Xyotec Capsule 200 is indicated for the management of infections caused by dermatophytes, yeasts, and molds, including but not limited to onychomycosis, histoplasmosis, blastomycosis, aspergillosis, and candidiasis. The capsule formulation ensures optimal bioavailability and convenient oral administration. Dosage and duration of therapy depend on the type and severity of infection, patient response, and clinical judgment. It is essential to administer Xyotec with food to enhance absorption. Caution is advised in patients with hepatic impairment, and liver function tests should be monitored periodically during treatment. Potential drug interactions exist due to itraconazole’s inhibition of cytochrome P450 enzymes, necessitating careful review of concomitant medications. Common adverse effects include gastrointestinal disturbances, headache, and rash. Xyotec Capsule 200 should be used under medical supervision, with adherence to prescribed dosage to ensure efficacy and minimize resistance development.